Researchers developed camelid-derived ubiquibodies designed to selectively degrade pathogenic mutant CRX transcription factor proteins. Published in Cell Communication and Signaling, the proof-of-concept work targets frameshift-generated CRX variants that escape standard degradation pathways. The platform uses engineered molecules to recruit the cellular ubiquitin-proteasome system toward mutant-specific CRX epitopes. The team reports that about two-thirds of known pathogenic CRX variants arise from frameshift mutations that share common C-terminal epitopes, enabling a single targeting approach to cover multiple mutants. In experiments using a truncated protein encoded by the p.G122Afs*65 variant, engineered ubiquibodies reduced mutant protein levels via proteasome-mediated clearance, exceeding clearance of wild-type CRX. The results support a route for therapies in dominant inherited retinal dystrophies driven by toxic protein accumulation.
Get the Daily Brief